Magnetic DIagnostic Assay for neurodegenerative diseases (MaDiA)

  • Santin, Matteo (PI)
  • Phillips, Gary (PI)
  • Perugini, Valeria (CoI)
  • Guildford, Anna (CoI)

Project Details


The Magnetic Diagnostic Assay for Neurodegenerative Diseases (MaDiA) project is focused on developing a versatile and cost-effective tool for early diagnosis of Alzheimer’s and Parkinson’s diseases.

The European Commission has awarded €3.9 million in funding for this three-year project; our research team, led by Professor Matteo Santin and Dr Gary Phillips, has received €530,986 and will collaborate with international partners from the Czech Republic, Germany, Italy and Spain.

Alzheimer’s is the most common form of dementia in the UK, affecting an estimated 850,000 people in the UK and seven million across Europe. Neurodegenerative diseases such as Alzheimer’s, and Parkinson’s (which is the second most common neurodegenerative disorder worldwide) are debilitating and largely untreatable conditions that are strongly linked with age. It costs around €130 billion a year to care for people with dementia across Europe, meaning that age-related neurodegenerative disease is one of the largest medical and societal challenges faced by our society.

The main aim of this research is to develop a reliable and affordable tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Researchers will use MaDiA technology, applying an array of magnetic sensors integrated into a microfluidics device and capable of recognising biomarkers obtained from cerebrospinal fluid or blood samples. Early diagnosis will improve the efficacy of current therapies which have been shown to slow the progression, particularly of Parkinson’s disease, as currently there is no cure for either disease.

MaDiA focuses on the application of an array of Magnetic Sensors capable of recognising targeted core and downstream biomarkers (BM) obtained from treated cerebrospinal fluid (CSF) or blood samples. MaDiA will develop a cost effective device for the analysis of CSF and blood samples for the detection of the already validated or innovative biomarkers, designed to become a reference Alzheimer’s (AD) and Parkinson (PD) diseases diagnostic tool in the standard clinical practice with good premises to function in the point of care regime. Moreover, diagnosis of AD or PD at early stages will become crucial in order to improve efficacy of the current therapy and the development and success of clinical trials.
Effective start/end date1/01/1731/12/19


  • Horizon 2020


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.